Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Longeveron Inc logo — Cell-Based Therapies

Longeveron Inc

Cell-Based Therapies

Founded 2014 United States Miami, United States 29 employees Post-IPO Equity Total: $34.01M Biotechnology, Health and Wellness +1

General Information

Company Name Longeveron Inc
Founded Year 2014
Location United States Miami, United States
Employees 29
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Longeveron Inc. To contact Longeveron Inc, visit longeveron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Longeveron Inc

Longeveron Inc is a biotechnology company that focuses on developing cellular therapies for aging-related and life-threatening conditions. The company's flagship product, Lomecel-B™, consists of culture-expanded medicinal signaling cells (MSCs) derived from the bone marrow of young healthy adult donors. Longeveron Inc aims to harness the regenerative properties of these cells to develop safe and effective therapies for challenging diseases associated with aging. The company is currently engaged in Phase 1 and 2 clinical trials for indications such as Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Longeveron Inc's ultimate goal is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the intention of achieving regulatory approvals, subsequent commercialization, and widespread adoption by the healthcare community. Longeveron Inc's philosophy revolves around the belief that regenerative medicine approaches can lead to significant improvements in healthy aging. The company's clinical data suggests that Lomecel-B™ addresses multiple aging-related processes simultaneously, including the decline in immune system function, blood vessel functioning, chronic inflammation, and MSC depletion. Established in 2014 and headquartered in the United States, the company secured a $4.40M Post-IPO Equity investment on June 17, 2024. Amid an aging global population and the increasing prevalence of age-related diseases, Longeveron Inc's innovative approach to cellular therapies positions it at the forefront of addressing the healthcare challenges associated with aging.

Taxonomy: cell-based therapies, clinical-stage biotech, regenerative medicine, MSC therapy, aging-related diseases, clinical trials, Lomecel-B™, healthspan, aging frailty, Alzheimer's disease, hypoplastic left heart syndrome, regulatory approvals, immune system function, public health advancements

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $9.00M -
18 Jul 2024
Post IPO Equity $4.40M -
17 Jun 2024
Post IPO Equity $5.25M -
08 Apr 2024
Post IPO Equity $2.36M -
21 Dec 2023
Post IPO Equity $4.00M -
12 Oct 2023
Grant $3.00M 1
Alzheimer's Association
23 Jul 2019
Grant $3.80M 1
National Institutes of Health
18 Oct 2018
Grant $750.00K 1
TEDCO
TEDCO
22 May 2018
Grant $1.15M -
09 Jan 2018
Seed Round $299.97K -
03 Nov 2017

Longeveron Inc Alternatives & Competitors

Longeveron Inc vs
Taiga Biotechnologies
Taiga Biotechnologies United States

Taiga Biotechnologies is a clinical stage biotechnology company focused on harnessing the power of t...

Seed
1 employees
Biotechnology, Health and Wellness
Longeveron Inc vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Longeveron Inc vs
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Israel

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenera...

Post-IPO Equity
36 employees
Biotechnology, Health Care

FAQ About Longeveron Inc

Cell-Based Therapies
Longeveron Inc was founded in 2014.
Longeveron Inc is headquartered in Miami, United States.
Longeveron Inc operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on cell-based therapies, clinical-stage biotech, regenerative medicine and MSC therapy.
Longeveron Inc has approximately 29 employees.
Longeveron Inc has completed 10 funding rounds, raising a total of $34.01M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Longeveron Inc include Taiga Biotechnologies, Taysha Gene Therapies, Brainstorm Cell Therapeutics, Elixirgen Therapeutics, Inc., Xenikos B.V.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Longeveron Inc and Taiga Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Longeveron Inc, https://bouncewatch.com/company/longeveron-inc, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes